GMDAQ vs. GMDA, ELOX, ALBT, KRBP, SQZ, FNCH, TCON, TCBP, ACORQ, and SCNI
Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include Gamida Cell (GMDA), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Kiromic BioPharma (KRBP), SQZ Biotechnologies (SQZ), Finch Therapeutics Group (FNCH), TRACON Pharmaceuticals (TCON), TC Biopharm (TCBP), Acorda Therapeutics (ACORQ), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDAQ) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Gamida Cell received 112 more outperform votes than Gamida Cell when rated by MarketBeat users.
Gamida Cell has a consensus price target of $4.75, indicating a potential upside of 31,461.46%. Given Gamida Cell's higher possible upside, analysts plainly believe Gamida Cell is more favorable than Gamida Cell.
50.3% of Gamida Cell shares are held by institutional investors. Comparatively, 50.3% of Gamida Cell shares are held by institutional investors. 6.7% of Gamida Cell shares are held by insiders. Comparatively, 3.4% of Gamida Cell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Gamida Cell has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
In the previous week, Gamida Cell's average media sentiment score of 0.00 equaled Gamida Cell'saverage media sentiment score.
Summary
Gamida Cell beats Gamida Cell on 5 of the 8 factors compared between the two stocks.
Get Gamida Cell News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMDAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMDAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GMDAQ vs. The Competition
Gamida Cell Competitors List
Related Companies and Tools
